BioStock Feed

2026-05-08 13:10:00 Curasight nears topline results in brain and prostate cancer

2026-05-08 10:10:00 Spago Nanomedical reaches primary endpoint in Tumorad-01

2026-05-06 11:29:00 SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout

2026-04-28 12:15:00 Pila Pharma on the preclinical results and the way forward

2026-04-28 12:15:00 Pila Pharma om de prekliniska resultaten och vägen framåt

2026-04-27 09:07:00 What good data looks like: SynAct Pharma ahead of its ADVANCE readout

2026-04-27 07:07:00 Zelluna entering the clinic with promising TCR-NK therapy

2026-04-27 07:07:00 Zelluna går in i klinik med lovande TCR-NK-terapi

2026-04-22 13:45:00 BioStock launches new TV format: Market Signal

2026-04-22 13:45:00 BioStock lanserar nytt TV-format: Market Signal

2026-04-20 08:42:00 ExpreS2ion Biotech advances breast cancer project with rights issue of SEK 53 million

2026-04-20 08:42:00 ExpreS2ion Biotech avancerar bröstcancerprojekt med företrädesemission om 53 Mkr

2026-04-17 09:58:00 Correction: Pila Pharma’s unanticipated obesity results plausibly explained by low drug exposure, analyses confirms

2026-04-17 09:58:00 Rättelse: Analys bekräftar att Pila Pharmas prekliniska resultat förklaras sannolikt av låg läkemedelsexponering

2026-04-17 08:34:00 Pila Pharmas preclinical results plausibly explained by low drug exposure

2026-04-17 08:34:00 Pila Pharmas prekliniska resultat förklaras sannolikt av låg läkemedelsexponering

2026-04-07 14:24:00 Biosergen halts BSG005 development

2026-03-26 11:27:00 Curasight welcomes international radiopharma experts to the board

2026-03-25 15:08:00 Pila Pharma updates from Bio-Europe Spring in Lisbon

2026-03-25 15:08:00 Pila Pharma uppdaterar från Bio-Europe Spring i Lissabon

2026-03-20 08:43:00 FluoGuide receives FDA Fast Track designation for FG001 in high-grade glioma

2026-03-20 08:43:00 FluoGuide erhåller FDA fast track-status för FG001 vid höggradigt gliom

2026-03-18 09:11:00 SynAct Pharma lays out dual strategy for resolution therapy at capital markets day

2026-03-12 14:02:00 Saniona enters clinical execution phase following transformational year

2026-03-09 16:52:00 Curasight reduces debt through Fenja Capital conversion

2026-03-03 08:43:00 SynAct Pharma secures 51,9 million SEK to strengthen clinical runway

2026-02-26 15:15:00 Curasight’s 2025: A pivotal year of therapeutic advancement and clinical momentum

2026-02-25 16:33:00 FluoGuide comments on the annual report and road ahead

2026-02-25 16:33:00 FluoGuide kommenterar rapporten och framtidsplanerna

2026-02-23 12:10:00 BioStock Launches ”Nordic Life Science Weekly” – A Strategic Deep Dive into the Nordic Ecosystem

2026-02-23 12:10:00 BioStock lanserar ”Nordic Life Science Weekly” – en strategisk genomgång av det nordiska ekosystemet

2026-02-20 08:40:00 Topline results on the horizon for SynAct Pharma

2026-02-19 07:41:00 SynAct Pharma on dual studies, partner interest and commercial potential

2026-02-19 07:41:00 SynAct Pharma om dubbla studier, partnerintresse och kommersiell potential

2026-02-19 07:35:00 Pila Pharma stärker kassan och finansierar klinisk fetmastudie

2026-02-19 07:35:00 Pila Pharma boosts financial runway and fully funds clinical obesity study

2026-02-12 14:51:00 Pila Pharma activates lucrative orphan drug track

2026-02-12 14:51:00 Pila Pharma aktiverar lukrativt spår inom särläkemedel

2026-02-03 14:34:00 ExpreS2ion Biotech reports encouraging initial data from cancer vaccine study

2026-02-03 14:34:00 ExpreS2ion Biotech rapporterar uppmuntrande initiala data från cancervaccinstudie

2026-02-02 07:28:00 Pila Pharma on preclinical data and the decision to proceed to the clinic

2026-02-02 07:28:00 Pila Pharma om prekliniska data och beslutet att gå vidare till klinik

2026-01-27 08:16:00 Pila Pharma prepares for clinical obesity trial despite inconclusive preclinical data

2026-01-27 08:16:00 Pila Pharma förbereder klinisk obesitasstudie trots inkonklusiva prekliniska data

2026-01-14 15:28:00 Curasight reports encouraging preliminary data from uTREAT Phase I study

2026-01-14 15:28:00 Curasight rapporterar uppmuntrande preliminära data från uTREAT fas I-studie

2026-01-13 09:33:00 Diamyd Medical: a Swedish example of Nobel Prize science in action

2026-01-13 09:33:00 Diamyd Medical: ett svenskt exempel på Nobelprisbelönad forskning i praktiken

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Vem äger bolaget?

BioStock

Prenumeration

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden